“9-Valent HPV Vaccine Safety and Tolerability in 16-26 Year Olds in Chongqing, China: A Study”

https://pubmed.ncbi.nlm.nih.gov/38112061

This study found that the 9-valent HPV vaccine is generally well-tolerated in individuals aged 16-26 years in Chongqing, China, with most adverse reactions being mild-to-moderate vaccination-site symptoms.